Xiamen Ade Biological Technology Co., Ltd. (hereinafter referred to as "the Company" or "Ade Biological") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
To further improve the management of director compensation and establish a scientific and effective incentive and restraint mechanism, the Company has formulated the 2026 director compensation plan in accordance with the "Guidelines for Corporate Governance of Listed Companies," "Articles of Association," "Compensation Management System for Directors and Senior Management," and other relevant regulations, considering the Company's operational development and referencing industry and regional compensation levels. The relevant details are as follows:
1. Applicable Objects
Company Directors